Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints

Area of Science:

• Genetics and Molecular Biology
• Cancer Therapeutics
• Cell Biology

Background:

• Topoisomerase II (TopoII) is a critical enzyme for genome integrity, targeted by established cancer therapies.
• Current TopoII-targeting agents, poisons and catalytic inhibitors, face limitations including normal tissue toxicity, partly due to TopoIIb inhibition.
• Cell cycle checkpoints, particularly the G2/M phase, significantly influence sensitivity and resistance to these agents.

Purpose of the Study:

• To review the function of TopoII and its role in cancer therapy.
• To analyze the mechanisms, limitations, and effects of current TopoII inhibitors on cell cycle checkpoints.
• To explore novel therapeutic strategies targeting TopoII and its associated checkpoints for improved cancer treatment.

Main Methods:

• Literature review of Topoisomerase II function and its inhibitors.
• Analysis of existing anti-cancer mechanisms and their impact on cell cycle checkpoints.
• Assessment of potential new therapeutic targets within the TopoII pathway.

Main Results:

• TopoII poisons are clinically used but exhibit significant normal tissue toxicity.
• Cell cycle checkpoints play a key role in determining patient response to TopoII-targeting drugs.
• The ATM-dependent decatenation checkpoint is identified as a potential target for selective cancer therapy.

Conclusions:

• Current TopoII inhibitors have limitations, necessitating exploration of new therapeutic avenues.
• Targeting the decatenation checkpoint offers a promising strategy to enhance cancer therapy selectivity.
• Modulating cell cycle checkpoints presents a potential alternative or complementary approach to improve treatment efficacy and reduce toxicity.